The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …

Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …

Abstract The SARS-CoV-2 Omicron variant (B. 1.1. 529) has multiple spike protein
mutations, that contribute to viral escape from antibody neutralization,,–and reduce vaccine …

The highly mutated SARS-CoV-2 Omicron (B. 1.1. 529) variant has been shown to evade a
substantial fraction of neutralizing antibody responses elicited by current vaccines that …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B. 1.1. 529)
variant is highly transmissible with potential immune escape. We conducted a test-negative …

We address whether T cell responses induced by different vaccine platforms (mRNA-1273,
BNT162b2, Ad26. COV2. S, and NVX-CoV2373) cross-recognize early SARS-CoV-2 …

The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.
1/B. 1.1. 529) harboring up to 36 mutations in spike protein, the target of neutralizing …

Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …